AngioDynamics, Inc. ANGO reported an adjusted loss per share of 11 cents for first-quarter fiscal 2025, against the year-ago ...

Throughout the last three months, 4 analysts have evaluated AngioDynamics ANGO -7.14% Get Free Report , offering a diverse ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AngioDynamics (ANGO – Research Report) today and set a price target of $14.00.

Q1 2025 Earnings Call Transcript October 3, 2024 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.11, ...

AngioDynamics (ANGO) stock falls 14% as the company misses estimates with its Q1 revenue, but beats on the bottom line. Read ...

For the year, the company backed its outlook for sales of between $282 million and $288 million and an adjusted loss between 42 cents a share and 38 cents a share. Analysts surveyed by FactSet are ...

Shares of AngioDynamics ( ANGO -4.24%) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came ...

Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

AngioDynamics posted first-quarter adjusted loss of 11 cents per share, compared to market estimates of a loss of 15 cents per share. The company's quarterly sales came in at $67.491 million versus ...

For the full year, AngioDynamics expects net sales to be in the range of $282 to $288 million, and adjusted loss per share of between $0.38 and $0.42. Analysts expect the company to report a loss of ...

AngioDynamics swung to a loss in its fiscal first quarter, although better than feared, and said it continues to expect sales growth in fiscal 2025.

AngioDynamics expects full-year earnings in the range of 38 cents to 42 cents per share, with revenue in the range of $282 million to $288 million. AngioDynamics shares have decreased slightly more ...